semaj83/ctmatch_classification huggingface dataset:
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-30.0,  Schistosomiasis Bilharziasis Urinary Schistosomiasis All subjects had to meet the study within 21 days prior to treatment Caucasian volunteers No smoker biological parameters (haematological, biochemical, renal and hepatic) in normal range Health Insurance sign inform consent  inflammatory or immunological pathology such as atopic diseases, evidence of inflammation or acute infection (including positive serology to viral hepatitis B and C or HIV) any immunological deficiency any clinically relevant alcohol or drug use (cannabis, opiates, cocaine, amphetamines, benzodiazepines, nicotine, barbiturates, meprobamate or antidepressant drugs according to urine drug and metabolites screen) current immunosuppressor treatment any other medication use within 2 weeks before the study any vaccination within the last 6 months no antibodies against Sh28GST protein
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Systemic Lupus Erythematosus Patients with systemic Lupus erythematosus  Patients without systemic Lupus erythematosus
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Immune Thrombocytopenia Systemic Lupus Erythematosus Patients older than 18 years old Immune Thrombopenia according to the American Society of Hematology (ASH) guidelines 2011 Positive antinuclear antibodies > 1/160e on Hep2 cells  Secondary ITP (eg HIV, HCV, HBV, lymphoproliferative disorders...)
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cutaneous Lupus Erythematosus-Systemic Lupus Erythematosus Patients diagnosed as cutaneous lupus erythematosus (CLE)  Patients receiving corticosteroid more than 15mg/day of the equivalent dose of prednisolone Patients whose CLASI activity scores were less than 4 point at the initiation of Screening (Visit 1) and Day1 (Visit 2) (evaluated by a dermatology specialist) Patients whose fluctuations of CLASI activity scores were ≥20% between Visit 1 and Visit 2 (evaluated by a dermatology specialist). The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Systemic Lupus Erythematosus Have completed the BEL113750 Protocol in Northeast Asia through Week 48 Be able to receive the first dose of belimumab for BEL114333 four weeks (minimum of 2 weeks, maximum of 8 weeks) after the last dose in BEL113750  Have developed clinical evidence of significant, unstable or uncontrolled, acute or chronic diseases not due to SLE (i.e., cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, malignancy or infectious diseases), or experienced an adverse event (AE) in the Phase 3 study that could, in the opinion of the principal investigator, put the subject at undue risk Have developed any other medical diseases (e.g., cardiopulmonary), laboratory abnormalities, or conditions (e.g., poor venous access) that in the opinion of the principal investigator, makes the subject unstable for the study
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Systemic Lupus Erythematosus Key Black race Clinical diagnosis of SLE by American College of Rheumatology (ACR) criteria Active SLE disease Autoantibody-positive On stable SLE treatment regimen which may corticosteroids (for example, prednisone), antimalarial (for example, hydroxychloroquine) and/or immunosuppressants (for example, azathioprine, methotrexate, mycophenolate) Key  Pregnant or nursing Have received treatment with any B cell targeted therapy (for example, rituximab or belimumab) at any time Have received treatment with an investigational biological agent in the past year Have received intravenous (IV) cyclophosphamide within the past 90 days Have severe active lupus kidney disease Have severe active central nervous system (CNS) lupus Have required management of acute or chronic infections within the past 60 days Have current drug or alcohol abuse or dependence Tested positive for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C Have a history of severe allergic reaction to contrast agents or biological medicines
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 5.0-17.0,  Systemic Lupus Erythematosus years to 17 years of age at enrollment Have a clinical diagnosis of SLE according to the American College of Rheumatology (ACR) classification criteria Have active SLE disease (SELENA score ≥ 6) Have positive anti-nuclear antibody (ANA) test results Are on a stable SLE treatment regimen at a fixed dose for a period of at least 30 days prior to Day 0 Females of childbearing age are willing to use appropriate contraception Subject age appropriate assent and parent or legal guardian informed consent to participate  Pregnant or nursing Have received treatment with belimumab (BENLYSTA®) at any time. (BENLYSTA® is a registered trademark of the GSK group of companies.) Treatment with any B cell targeted therapy (for example, rituximab) or an investigational biological agent in the past year Have received anti-TNF therapy; Interleukin-1 receptor antagonist; IVIG; or plasmapheresis within 90 days of Day 0 Have received high dose prednisone or equivalent (>1.5mg/kg/day) within 60 days of baseline Have received intravenous (IV) cyclophosphamide within 60 days of Day 0 Have received any new immunosuppressive/immunomodulatory agent, anti-malarial agent within 60 days of baseline Have severe lupus kidney disease Have active central nervous system (CNS) lupus Have had a major organ transplant
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Inflammation Systemic Lupus Erythematosus Men and women (not pregnant and not nursing) Subjects with SLE meeting the American College of Rheumatology (ACR) with a disease duration of at least 6 months Subjects with clinically active SLE defined as a Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score of at least 6 and positive for antinuclear antibody (ANA) and/or Anti-double-stranded DNA antibody (anti-dsDNA) If taken, background medication must be stable  Presence or history of active lupus nephritis (LN) within the last 4 months or active central nervous system (CNS) disease within the last 12 months Body mass index (BMI) below 18 kg/m^2 or above 38 kg/m^2
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 12.0-60.0,  Systemic Lupus Erythematosus The American College of Rheumatology established eleven in 1982,which were revised in 1997 as a classificatory instrument to operationalise the definition of SLE in clinical trials Malar rash (rash on cheeks) Discoid rash (red, scaly patches on skin that cause scarring) Serositis: Pleurisy (inflammation of the membrane around the lungs) or pericarditis (inflammation of the membrane around the heart) Oral ulcers (includes oral or nasopharyngeal ulcers) Arthritis: nonerosive arthritis of two or more peripheral joints, with tenderness, swelling, or effusion Photosensitivity (exposure to ultraviolet light causes rash, or other symptoms of SLE flareups) Blood—hematologic disorder—hemolytic anemia (low red blood cell count) or leukopenia (white blood cell count<4000/µl), lymphopenia (<1500/µl) or thrombocytopenia (<100000/µl) in the absence of offending drug. Hypocomplementemia is also seen, due to either consumption of C3 and C4 by immune complex-induced inflammation or to congenitally complement deficiency, which may predispose to SLE Renal disorder: More than 0.5 g per day protein in urine or cellular casts seen in urine under a microscope Antinuclear antibody test positive  Poor compliance With lupus mental damage complication, occurrence of epilepsy or unable to express subjective symptoms during the observation period Taking drugs that affect cytochrome P450 2B6, cytochrome P450 3A4 and cytochrome P450 2C19, except corticosteroids Abnormal liver function
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Systemic Lupus Erythematosus Key Clinical diagnosis of SLE by American College of Rheumatology (ACR) criteria Active SLE disease Autoantibody-positive On stable SLE treatment regimen which may corticosteroids (for example, prednisone), antimalarial (for example, hydroxychloroquine) and/or immunosuppressants (for example, azathioprine, methotrexate, mycophenolate) Key  Pregnant or nursing Have received treatment with any of the following: belimumab, either as a marketed product or as an investigational agent; any B cell targeted therapy (for example, rituximab) in the past year; or any biological agent (for example, adalimumab, etanercept, infliximab, or anakinra) in the past 90 days Have received a live vaccine within the past 30 days Have severe active lupus kidney disease Have severe active central nervous system (CNS) lupus Current or past positive for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Systemic Lupus Erythematosus Key Clinical diagnosis of active SLE Autoantibody-positive Current SLE treatment includes and/or immunosuppressants (for example, azathioprine, methotrexate, cyclophosphamide, mycophenolate, and biologics) Key  Have received treatment with an investigational agent within the past year Are currently enrolled in a placebo-controlled (belimumab) clinical trial or a continuation trial in which belimumab is used as an investigational agent Have a history of exposure, but are not currently receiving Current SLE treatment includes only an antimalarial (for example, hydroxychloroquine) or only steroids
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Antiphospholipid Syndrome Persistent(at least 12 weeks apart)aPL-positivity within 12 months prior to the screening defined as aCL IgG/M (>40U,medium-to-high titer,and/or greater than the 99th percentile)and/or aβ2GPI IgG/M(>40U, medium-to-high titer, and/or greater than the 99th percentile)and/or Positive LA test based on the International Society of Thrombosis & Haematosis Recommendations Selected  History of thrombosis (arterial, venous, and/or biopsy proven microthrombosis History of Transient Ischemic Attack Confirmed by a Neurologist SLE Diagnosis based on the ACR Classification > 4/11 Other Systemic Autoimmune Diseases diagnosed based on ACR Classification Current Hydroxychloroquine or another antimalarial treatment (-3 months) Current warfarin treatment (-3 months) Current heparin therapy( -3 months) Current pregnancy History of Hydroxychloroquine eye toxicity History of Hydroxychloroquine allergy
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Lupus Erythematosus, Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus, Discoid have active DLE or active SCLE confirmed by histological analysis have a confirmed diagnosis of SLE with SLE Disease Activity Index (SLEDAI) of >6 and current or historical positive ANA or anti-dsDNA have an active skin lesion that can be biopsied if using hydroxychloroquine or chloroquine, must be on stable doses for at least 2 months prior to screening  have an active skin disease other than CLE have any known malignancy within the previous 5 years (with the exception of a non-melanoma skin cancer that has been treated with no evidence of recurrence) have used a topical corticosteroid on active lesion have donated blood (volume >=500 mL) within 56 days prior to screening has been treated with drugs that are associated with CLE induction within 2 months prior to the screening have been treated with >10 mg/day prednisone therapy or equivalent in the last 4 weeks prior to screening
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Eyebrow Hypotrichosis Thin Eyebrow male or female aged 18-60 years hypotrichosis of eyebrows healthy informed consent obtained  underlying diseases alopecia areata or trichotillomania thyroid diseases pregnancy or breast feeding previous eyebrow tattoo, trauma or accident history of eyebrow or hair medications in 6 months history of minoxidil or its ingredient allergy history of eyebrow surgery
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cetuximab-induced Papulopustular (Acneiform) Rash Who Have Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma Patients 18 years or older with underlying diagnosis of metastatic colorectal cancer or head and neck squamous cell carcinoma including newly diagnosed patient Patients must provide written informed consent to participate in the study Anticipated initiation of cetuximab treatment with or without additional chemotherapy Able to self-administer topical interventions or provide for another person to apply the topical interventions  Females of childbearing potential who are pregnant or nursing Patients with allergy, hypersensitivity or other contraindication to dapsone, sulfa antibiotics, or excipients of the dapsone gel product Patients with pre-existing dermatologic condition affecting the face and chest that would impair assessment of papulopustular rash including dense and/or long facial hair (per investigator discretion) Patients currently using prescription and/or over-the-counter topical medications to the face and/or chest who are unwilling to discontinue use during the trial intervention period (day 0 ± 2 days through day 28 ± 2 days) Previous or concurrent radiation therapy to head, neck, and chest (i.e. application sites only) Previous therapy with cetuximab within 6 months of consent
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Systemic Lupus Erythematosus SLE Able and willing to give written informed consent and comply with requirements of the study Age 18 years, inclusive, at randomization Diagnosis of SLE, per ACR [32] m-SLEDAI score < 4 at screening visit (SLEDAI score without serologies) Physician Global Assessment (0-3) score of 1 or less at screening visit On a stable dose of MMF (1000-3000 mg/day) for at least 12 weeks prior to randomization Total duration of stable or decreasing MMF therapy must be at least two years for subjects initiating MMF for renal indications (with or without concurrent extra-renal manifestations), or one year for subjects initiating MMF for extra-renal indications  A history of life-threatening neuropsychiatric SLE within 1 calendar year prior to randomization Any of the following laboratory abnormalities at the screening visit Proteinuria as defined by a spot protein/creatinine ratio > 1.0 mg/mg Serum creatinine > 2.0 mg/dL Transaminases > 2.5x the upper limit of normal (ULN) Hemoglobin < 9 g/dL, unless the subject has documented hemoglobinopathy White blood count (WBC) < 2000/mm3 (equivalent to < 2 x109/L) Neutrophils < 1000/mm3 (equivalent to < 1 x109/L) Platelet count < 75,000/mm3 (equivalent to < 75 x 109/L) Prednisone > 25 mg/day (or its equivalent) within 24 weeks prior to randomization for lupus activity
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Alopecia Areata Patients between 18 to 75 years of age Patients with a diagnosis of patch type alopecia areata Patients will have >30% and <95% total scalp hair loss at baseline as measured using the SALT score. Two patients with current episodes of alopecia totalis/universalis may be included in this study Duration of hair loss greater than 3 months No evidence of regrowth present at baseline Patients may be naïve to treatment or unresponsive to intralesional (IL) steroids or other treatments for alopecia areata  Patients with a history of or active skin disease on the scalp such as psoriasis or seborrheic dermatitis Patients in whom the diagnosis of alopecia areata is in question Patients with active medical conditions or malignancies (except adequately treated basal or squamous cell carcinoma) that in the opinion of the investigator would increase the risks associated with study participation, including patients with a history of recurrent infections Women of childbearing potential who are unable or unwilling to use two forms of birth control for the study duration Women who are pregnant or nursing Patients known to be HIV or hepatitis B or C positive Patients with history or evidence of hematopoietic abnormality Patients with <200K platelet count at baseline Patients with history or evidence of renal or hepatic impairment Patients with history of immunosuppression or history of recurrent serious infections